www.eisai.com website review
Improve your SEO :: free trial!
www.eisai.com is 72% geoptimaliseerd!
SEO Keyword summary for www.eisai.com/news/index2016.html
Keywords are extracted from the main content of your website and are the primary indicator of the words this page could rank for. By frequenty count we expect your focus keyword to be eisai
Focus keyword
Short and long tail
Short Tail Keywords eisai release close |
long Tail Keywords (2 words) 2016 eisai news release anticancer agent release worldwide worldwide japanese |
long Tail Keywords (3 words) worldwide japanese contact release worldwide japanese japanese contact us contact us search us search close news release worldwide search close close |
www.eisai.com On-Page SEO Scan
Descriptive Elements
The <head> element of a www.eisai.com/news/index2016.html page is used to inform the browser and visitors of the page about the general meta information. The head section of the page is where we place the page title, the definition of the HTML version used, the language of in which the page is written. In the head section we can also include JavaScript and CSS (markup) files for the page.
Page title
Title length
news releaseiumlfrac eisai ltd
Meta description
Meta description legth
Meta description SEO
welcome eisai official corporate website eisais news release
Content SEO
Number of Words
Spam detected?
Headings
Heading distribution
Heading normalisation
Heading SEO impact
Emphasis (bold and italic)
Emphasis SEO impact
Images
Number of images
Images dimensions
Image alt descriptions
Images SEO impact
newsindexhtml back top hhc human health care facebook linkedin
Mobile SEO www.eisai.com/news/index2016.html
Mobile rendering
Mobile optimizations
Responsive design detected (mobile css)
No flash detected !
Mobile improvement
Marketing / lead generation for www.eisai.com/news/index2016.html
Social Media
Facebook shares | Facebook likes | ||
Facebook comments | Tweets | ||
Google +1 |
Conversion form
Search form
Analytics
Online presence
SERP Preview
SERP Title
SERP Link
SERP Description
Domain Level SEO
Domain name
13 characters long
Domain name SEO Impact
Path name
new found in path !
news found in path !
Structured data
Publisher Markup
Other Structured data
Website configuration
Correct processing of non-existing pages?
Favicon icon found?
HTML request without WWW redirected correctly?
Robots.txt found?
Sitemap found?
Navigation and internal links
Navigation
Url seperator
Human readable urls
Number of links
Link SEO Impact
aboutsite terms of use
|
accessibility accessibility
|
community_guidelines sns community guidelines
|
company worldwide
corporate governance
about eisai
message from top management
corporate concept
corporate information
business activities
video library
eisai at a glance
corporate executives
japan business sites
eisai the first 80 years
basic approach to corporate governance
corporate governance system
board of directors and committees
related rules
compensation for corporate executives
internal audit
products
production and logistics demand chain systems
|
hhc eisais hhc concept
|
innovation innovation
research and development rd
hhceco the hhc concept ecosystem
open innovation
corporate venture capital
eisais drug discovery research and development sites worldwide
flow of rd drug creation research
latest major rd pipeline
key therapeutic areas
clinical trials
use of digital technology
policies and guidelines
collaboration with partners
|
inquiry contact us
|
ir investors
management policy
ir library
financial data
ir events calendar
stock bond information
ir site map
mediumterm business plan eway future beyond
basic policy for capital strategy
basic policies regarding persons to control the determination of financial and business policies of the company
eisai group disclosure policy
financial reports
shareholder reports
value creation report environmental report human capital report
presentations
financial highlights
fact sheet
ir calendar
stock information
bonds and ratings
analyst coverage
general meeting of shareholders
|
news 2023 release
eisai and keio university to establish a new industryacademia collaboration siteaccelerating the discovery of novel drug targets that may lead to development of new therapeutics for dementia
antiobesity agent belviq approved in brazil
anticancer agent treakisym approved in japan for additional indication as firstline treatment for lowgrade bcell nonhodgkins lymphoma and mantle cell lymphoma
eisai presents latest data on bace inhibitor elenbecestate2609 at 9th clinical trials on alzheimers disease
interim analysis of phase ib study of eribulin and pembrolizumab combination regimen in metastatic triple negative breast cancer presented at san antonio breast cancer symposium
eisai to present latest data on perampanel and rufinamide at 70th american epilepsy society annual meeting
eisai to present latest data on eribulin at 39th annual san antonio breast cancer symposium
us fda grants fast track designation for the development of eisais bace inhibitor e2609 for early alzheimers disease
statement regarding the results of the access to medicine index 2016
uk nice recommends anticancer agent halaven as treatment for advanced breast cancer
enrollment commences in phase clinical study of eisais bace inhibitor e2609 in early alzheimers disease
notification regarding revision of consolidated financial forecasts ifrs for the fiscal year ending march 31 2017
eisai to initiate phase clinical study of dual orexin receptor antagonist lemborexant in patients with irregular sleepwake rhythm disorder and dementia
eisai to initiate two phase clinical studies for antiepileptic drug perampanel fycompa in pediatric patients with partialonset or primary generalized tonicclonic seizures and in patients with seizures associated with lennoxgastaut syndrome
application submitted for proton pump inhibitor pariet in japan seeking approval for additional dosage and administration for maintenance therapy of proton pump inhibitor resistant reflux esophagitis
eisai to officially launch chocola bb rich ceramide in stores nationwidejapans first food with function claims drink containing ceramidedrink to counter dry skin
preliminary phase ib clinical study results for lenvatinib in combination with pembrolizumab in selected solid tumors presented at esmo 2016
exclusive licensing agreement for inhouse developed monoclonal antibody farletuzumab in latin america concluded with eurofarma laboratrios sa
launch of uritos tablets for overactive bladder in thailand
belviq xr a new oncedaily formulation of belviq for chronic weight management now available in the united states
eisai to initiate phase clinical study of anticancer agent lenvatinib as potential firstline therapy for advanced renal cell carcinomasimultaneous development of two combination therapies lenvatinibeverolimus and lenvatinibpembrolizumab
eisai to present latest data on lenvatinib and eribulin at esmo congress 2016
abbvie and eisai obtain additional approval for new indication of fully human antitnf monoclonal antibody humira in the treatment of noninfectious uveitisthe first biologic treatment available for noninfectious intermediate posterior and panuveitis regardless of underlying disease
eisai commences provision of emily smartphone app to support living with epilepsy in japanfeatures localized sos notification for emergencies and easy communication via stamps
eisai submits supplemental application for partial label change for antiepileptic drug fycompa as monotherapy for treatment of partialonset seizures based on new us fda policy
eisai receives license for new indication for anticancer agent kisplyx lenvatinib mesylate for treatment of advanced renal cell carcinoma
eisai selected for fourth consecutive year of membership in dow jones sustainability asia pacific index 2016
anticancer agent treakisym for injection 100 mg approved in japan for additional indication of chronic lymphocytic leukemia
eisai to launch chocola bb mouth ulcer repair shotfirst mouth ulcer spray for the chocola bb brand
us fda confirms sufficient data to advance investigational bace inhibitor e2609 for treatment of early alzheimers disease to phase planning underway towards phase study initiation in fy2016
china food and drug administration accepts nda for anticancer agent halaven
continuation of policy for protection of the companys corporate value and common interests of shareholders shareholder rights plan
eisai and mamorio to jointly develop memamorio tracking tool to support people with dementia going out
eisai presents results of additional analysis of phase study of anticancer agent halaven at 14th jsmo annual meeting plenary session
notification regarding revision of consolidated financial forecasts ifrs
eisai receives positive chmp opinion on new indication for anticancer agent lenvatinib in combination with everolimus for treatment of advanced renal cell carcinoma
us fda approves belviq xr a oncedaily formulation of lorcaserin for chronic weight management
antiobesity agent venespri lorcaserin approved in mexicofirst country in latin america to approve lorcaserin
correction to notification regarding the continuation and partial revision of the performancerelated stock compensation system
ntt it ntt east and eisai rollout interprofessional collaboration business for medical treatment and care
eisai launches inhouse developed novel anticancer agent lenvima in mexico
eisai listed for 15th consecutive year in ftse4good index series an index for socially responsible investment
position and policy regarding reduction in the trading unit of the companys shares
abbvie eisai and ea pharma obtain additional approval for new dosing regimen of fully human antitnf monoclonal antibody humira in patients with crohns disease
notice regarding the recording of onetime income in association with acquisition of ea pharma shares
eisai launches new oral suspension formulation for antiepileptic drug fycompa perampanel in the united statesas adjunctive therapy for the treatment of partialonset seizures and primary generalized tonicclonic seizures in patients with epilepsy
eisai presents latest phase data on inhouse developed antifractalkine antibody e6011results suggest safety tolerability as well as clinical activity in rheumatoid arthritis and crohns disease
eisai inc enters into collaboration agreement to copromote eisais anticancer agent lenvima in combination with everolimus as treatment for advanced renal cell carcinoma in the united states
anticancer agent halaven approved in the philippines for new indication for treatment of soft tissue sarcomasecond country in asia after japan to approve halaven for soft tissue sarcoma
abbvie and eisai subsidiary ea pharma commence copromotion of fully human antitnf monoclonal antibody humira in the field of gastrointestinal disease
notification regarding the completion of the disposal of treasury stock through thirdparty allotment in accordance with the continuation of performancerelated stock compensation system
eisai to launch inhouse developed antiepileptic drug fycompa perampanel hydrate as adjunctive therapy for partialonset and generalized tonicclonic seizures in japan
eisai to present new research on oncology products and pipeline at 52nd asco annual meeting
us fda approves additional indication for eisais anticancer agent lenvima in combination with everolimus as treatment for advanced renal cell carcinoma
anticancer agent halaven demonstrates statistically significant extension in progression free survival compared to vinorelbine in phase clinical study of patients with breast cancer in china
notification regarding the disposal of treasury stock through thirdparty allotment in accordance with the continuation of performancerelated stock compensation system
notification regarding the continuation and partial revision of the performancerelated stock compensation system
eisai receives approval for new indication for anticancer agent halaven for treatment of advanced liposarcoma in europe
continuation of policy for protection of the companys corporate value and common interests of shareholders shareholder rights plan
eisai to support relief efforts for 2016 kumamoto earthquakes
eisai announces nonclinical research findings at aacr 107th annual meeting regarding combination of anticancer agent lenvatinib with everolimusenhanced mechanism of angiogenesis inhibition and antitumor activity in renal cell carcinoma investigated
aricept approved in the philippines for new indication as treatment for dementia with lewy bodiessecond country in the world after japan to approve aricept for dementia with lewy bodies
eisai receives positive chmp opinion on new indication for anticancer agent halaven for treatment of advanced liposarcoma
eisai transfers the rights to investigational anticancer agent e7777 for european us and certain emerging markets to dr reddys laboratories
eisai co ltd and ajinomoto co inc announce establishment of gastrointestinal specialty pharma ea pharma co ltd through the integration of eisais gastrointestinal disease business and ajinomoto pharmaceuticals co ltd
notification regarding revision of consolidated financial results forecasts ifrs for the fiscal year ending march 31 2016
eisais us subsidiary eisai inc enters share purchase agreement concerning akarx inc in the usrights to inhouse developed thrombocytopenia treatment avatrombopag to be transferred
notice concerning shelf registration for issuance of stock options
eisais inhouse developed antiepileptic drug fycompa perampanel hydrate approved in japan as adjunctive therapy for partialonset and generalized tonicclonic seizures
eisai withdraws new drug application for mecobalamin ultrahigh dose preparation as treatment for amyotrophic lateral sclerosis
joint promotion agreement on antiemetic agent with helsinn therapeutics inc in the united states revisedeisai to return all rights to promote and distribute akynzeo netupitantpalonosetron to helsinn therapeutics inc
notice regarding discontinuation of sales and voluntary recall of egg white lysozyme preparation neuzym
notification regarding change in representative corporate officers
eisais anticancer agent halaven newly approved in japan for treatment of soft tissue sarcoma
abbvie and eisai clear allcase surveillance condition for approval of humira a fully human antitnf monoclonal antibody in the treatment of polyarticular juvenile idiopathic arthritis
eisai and sysmex enter comprehensive agreement to create nextgeneration diagnostic reagents in the field of dementia
phase trial results of eisais anticancer agent halaven in soft tissue sarcoma published in the lancet
notification regarding revision of consolidated financial results forecasts ifrs for the fiscal year ending march 31 2016
eisai acquires exclusive license from huya bioscience international to develop and market hdac inhibitor hbi8000 in japan and other asian countries
us fda approves eisais anticancer agent halaven for the treatment of advanced liposarcoma
us fda accepts for priority review snda for eisais anticancer agent lenvatinib seeking approval for renal cell carcinoma
eisai submits new application in europe for inhouse developed anticancer agent lenvatinib seeking approval for indication covering renal cell carcinomaapplication based on results of phase clinical study
2022 release
2021 release
2020 release
2019 release
2018 release
2017 release
2016 release
2015 release
2014 release
2013 release
2012 release
2011 release
2010 release
2009 release
2008 release
2007 release
|
privacy privacy policy
|
sitemap sitemap
|
sustainability sustainability
message from top management
eisais sustainability
sustainability management
initiatives for improving access to medicines
environment
society
governance
esg data report
thirdparty assessment
system for promoting sustainability
eisais materiality material topics
sustainability advisory board
initiatives for sustainable development goals
member organizations and initiatives that engage in sustainabilityrelated activities
our concept for access to medicines
initiatives for elimination of neglected tropical diseases
initiatives for improving access to medicines for noncommunicable diseases
research development for improving access to medicines
environmental management
climate countermeasure
establishment of a recyclingoriented society
management of chemical substances
biodiversity conservation
respect for human rights
relationship with customers
relationship with our employees
relationship with business partners
relationship with industry associations and patient groups advocacy
relationship with people throughout society
compliance and risk management
global tax policy
information security
targets and results
esg data and independent assurance
gri content index
|
www.eisai.com |
Links to external pages
Outloing links
reg18.smp.ne.jp
www.eisai.co.jp
www.twitter.com
SEO Advice for www.eisai.com
In this section we provide pointers on how you can to optimize your web page so it can be found more easily by search engines and how to make it rank higher by optimizing the content of the page itself. For each of the individual criteria the maximum score is 100%. A score below 70% is considered to be indication that the page is not complying with general SEO standards and should be evaluated and/or fixed. Not every factor is weighted the same and some are not as important as others. Relatively unimportant factors like meta keywords are not included in the overall score.
Item | Factor | Pointers | |
---|---|---|---|
PageTitle | 100% | Far too many sites lack a page title. A page title is the first thing that shows in the search results so always use the title element. | |
Title relevance | 65% | A title should reflect the contents of a site. This site has a 50 % match | |
Title Length | 100% | Limit your title to anywhere between 40 and 70 characters. Your title was 51 characters long | |
Meta Description | 100% | A meta description is the second element that shows in the search results so always use the meta description. | |
Meta description length | 60% | The meta description should be between 145 and 160 characters. This meta description is 85 characters long. | |
Meta description relevance | 90% | Meta Description should reflect the contents of a site. This site has a 50 % match | |
Number of internal links | 30% | Linking to internal pages makes pages easier to find for search engines. Try to keep the number of links on your page roughly below 100. There are 288 internal links on this page. | |
Folder structure | 100% | We found a folder structure in the links on your page. A good folder structure makes a site easier to navigate. We found 12 level 1 folders and 104 folders above or in the first level of navigation. | |
Headings | 100% | Headers should reflect the contents of a site. This site has a 75 % match | |
Links | 10% | Link anchors should to some degree reflect the contents of a site. This site has a 5 % match | |
Image alt tags | 31% | Image alt tags should to some degree reflect the contents of a site. This site has a 11 % match | |
Bold and italic | 100% | Bold and italic tags should reflect the contents of a site to some degree. This site has a 100 % match | |
Html ratio | 100% | Try to keep the html / text ratio as low as possible. More html means longer loading times. Layout should be handled in a serpate css file | |
Image descriptions | 22% | 22.222222222222 % of all images have been described via the "alt" attribute. Describing images with relevant text may lead to better results in the search engines. | |
Page errors | 100% | Pages with no errors display significantly faster on most browsers. We detected 0 errors and warnings | |
WordCount | 20% | An ideal page contains between 400 and 600 words.This page contains 2345 words | |
Server response time | 30% | A slow server slows down a website. This server responds 908.61% slower the average | |
Gzip compression | 30% | This site does not use Gzip compression. Pages may not display as fast as they could | |
Keywords in Domainname | 100% | There are important keywords in your domain name | |
Keywords in domain path | 100% | There are important keywords in the domain path | |
Structured Data | 100% | Structured data makes it easier for search engines to index your website | |
Inline css | 93% | Do not use inline css declarations. Inline css will slow down the rendering of the website. We detected 2 inline style declarations ( <a style="color:green">) with a size of 60 bytes | |
Excessive use of the same words | 100% | There is no indication that there are one or more keywords that are used excessively. | |
Frames or iframes | 20% | The use of (i)frames can lead to problems crawling your page. Wij found 2 frame(s) on your page | |
Flash | 100% | Perfect, we detected no flash objects on your page | |
Css | 100% | Perfect, we did not detect too many CSS files | |
Javascript | 30% | Wij detected too much (4) blocking JavaScript files. Try to combine or defer the loading of JavaScript files | |
Mobile Website | 100% | Perfect, we found a responsive design for mobile users | |
Most important heading | 100% | Perfect, we detected a correct use of the most important (h1) heading! | |
Normalized headings | 100% | Perfect, we found a correct use of normalized headings ! |
How would you like to have SEO advice for all your pages ?? Start your SEO Dashboard and optimize your website!
www.eisai.com images and descriptions
7 images found at www.eisai.com Images can improve the user experience for a website by making a pag visually appealing Images can also add extra keyword relevance to a webpage by using alt tags. Images can also slow down a website. If the width and height for a picture is not specified for a browser know in advance how large the image is. A browser must first load the picture and see before it knows how much space should be on the page. Upon reservation In the meantime, the browser can do little but wait. When the height and width for the plate are given in the HTML code, a browser just continues to build for a page while the images load in the background.
http://www.eisai.com/common/images/header/logo.svg height: height attribute not set width: width attribute not set description: /news/index.html |
|
http://www.eisai.com/common/images/icon_search.png height: height attribute not set width: width attribute not set description: no alt description found |
|
http://www.eisai.com/common/images/footer/to-top.png height: height attribute not set width: width attribute not set description: back to top |
|
http://www.eisai.com/common/images/logo_hhc.svg height: height attribute not set width: width attribute not set description: hhc human health care |
|
http://www.eisai.com/common/images/x-icon.svg height: height attribute not set width: width attribute not set description: x |
|
http://www.eisai.com/common/images/facebook-icon.svg height: height attribute not set width: width attribute not set description: facebook |
|
http://www.eisai.com/common/images/linkedin-icon.svg height: height attribute not set width: width attribute not set description: linkedin |
How are images contributing to your SEO site-wise ? Your leading content tool has the awnsers!